|  |
| --- |
| 17 November 2023 |
| **Target achieved** | **Progress** | **Regress** |



**Antimicrobial resistance targets
How is the European Union doing?**

\*Population-weighted mean % consumption in ‘Access’ group.

**As defined in the AWaRe classification of the WHO**

**At least 65% of the total consumption of antibiotics in humans belongs to the
‘Access’ group of antibiotics**

\*\*Percentage point difference from 2019.

**-16.8%**

**59.8%**

**\***

**Number per 100 000 population**

**+49.7%**

**-12.2%**

**-2.5%**

**2030**

**TARGET**

**2.1**

**-5%**

**3.3**

**2022**

**2019
baseline**

**2.2**

**-**

**-10%**

**9.4**

**2030**

**TARGET**

**-**

**10.4**

**2019
baseline**

**2030**

**TARGET**

**4.8**

**-15%**

**2022**

**4.9**

**-**

**2019
baseline**

**5.6**

**-1.3%**

**\*\***

**2022**

**2019
baseline**

**61.1%**

**\***

**-**

**15.9**

**2030**

**TARGET**

**2022**

**-**

**19.9**

**2019
baseline**

**2022**

**8.7**

**-20%**

**+3.9%**

**\*\***

**65%**

**2030**

**TARGET**

**19.4**

**Reduce by 5% the total incidence of bloodstream infections with carbapenem-resistant
*Klebsiella pneumoniae***

**Number per 100 000 population**

**Reduce by 10% the total incidence of bloodstream infections with third-generation cephalosporin-resistant *Escherichia coli***

**Number per 100 000 population**

**Reduce by 15% the total incidence of bloodstream infections with meticillin-resistant *Staphylococcus aureus* (MRSA)**

**Defined daily doses (DDDs) per 1 000 inhabitants per day**

**Reduce by 20% the total consumption of antibiotics
in humans**